All In Biotech

NDA 210833 · Cosette

Sympazan

Clobazam · Oral · Benzodiazepine

Last checked: Nov 19, 2026Latest source record: Mar 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Nov 1, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

23

10 Phase 3, 2 recruiting

FAERS reports

17,678

15,318 serious, 1,245 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS ; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) , and Drug Interactions (7.1) ]. The use of benzodiazepines, including SYMPAZAN, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse...

What it is approved for

From the label in effect Dec 1, 2025.

SYMPAZAN ® is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older. SYMPAZAN ® is a benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older ( 1 ).

Mechanism: The exact mechanism of action for clobazam, a 1,5-benzodiazepine, is not fully understood but is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA A receptor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • SYMPAZAN · CLOBAZAM 20MG · FILM, ORAL · Prescription
  • SYMPAZAN · CLOBAZAM 5MG · FILM, ORAL · Prescription
  • SYMPAZAN · CLOBAZAM 10MG · FILM, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Clobazam" as an intervention, any sponsor and status, largest first.

All 23 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure3,075
  • drug ineffective2,717
  • off label use1,949
  • somnolence1,356
  • drug interaction1,059
  • epilepsy810
  • condition aggravated760
  • fatigue742
  • status epilepticus625
  • multiple-drug resistance584
  • generalised tonic-clonic seizure530
  • foetal exposure during pregnancy520

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200446
200573
200669
200784
2008111
2009127
2010168
2011127
2012299
2013273
2014296
2015392
2016385
2017542
2018894
20191,315
20201,354
20212,018
20221,616
20231,958
20242,167
20251,945
20261,418

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sympazan (Clobazam)

2024 spending

$2.6M

Beneficiaries

195

1,456 claims

Per beneficiary

$13,081

$33.57 per unit

View as table
YearSpending
2020$1,203,742
2021$1,594,939
2022$2,235,181
2023$2,541,059
2024$2,550,755

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 203 on PubMed

Sponsor: Cosette

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.